JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) - Net Assets

Latest as of March 2026: Rs41.59 Billion INR ≈ $449.80 Million USD

Based on the latest financial reports, JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has net assets worth Rs41.59 Billion INR (≈ $449.80 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs49.69 Billion ≈ $537.34 Million USD) and total liabilities (Rs8.09 Billion ≈ $87.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of JB Chemicals & Pharmaceuticals Limited to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets Rs41.59 Billion
% of Total Assets 83.71%
Annual Growth Rate 13.63%
5-Year Change 94.48%
10-Year Change 204.52%
Growth Volatility 10.98

JB Chemicals & Pharmaceuticals Limited - Net Assets Trend (2005–2026)

This chart illustrates how JB Chemicals & Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. See JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) liquidity interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for JB Chemicals & Pharmaceuticals Limited (2005–2026)

The table below shows the annual net assets of JB Chemicals & Pharmaceuticals Limited from 2005 to 2026. For live valuation and market cap data, see JB Chemicals & Pharmaceuticals Limited stock valuation.

Year Net Assets Change
2026-03-31 Rs41.59 Billion
≈ $449.80 Million
+21.14%
2025-03-31 Rs34.33 Billion
≈ $371.30 Million
+17.45%
2024-03-31 Rs29.23 Billion
≈ $316.15 Million
+17.86%
2023-03-31 Rs24.80 Billion
≈ $268.24 Million
+15.98%
2022-03-31 Rs21.39 Billion
≈ $231.28 Million
+17.93%
2021-03-31 Rs18.13 Billion
≈ $196.12 Million
+26.11%
2020-03-31 Rs14.38 Billion
≈ $155.51 Million
-3.03%
2019-03-31 Rs14.83 Billion
≈ $160.37 Million
+2.67%
2018-03-31 Rs14.44 Billion
≈ $156.20 Million
+5.75%
2017-03-31 Rs13.66 Billion
≈ $147.71 Million
+24.70%
2016-03-31 Rs10.95 Billion
≈ $118.46 Million
+10.10%
2015-03-31 Rs9.95 Billion
≈ $107.59 Million
-4.60%
2014-03-31 Rs10.43 Billion
≈ $112.78 Million
+2.21%
2013-03-31 Rs10.20 Billion
≈ $110.34 Million
+5.19%
2012-03-31 Rs9.70 Billion
≈ $104.90 Million
+40.26%
2011-03-31 Rs6.92 Billion
≈ $74.79 Million
+21.73%
2010-03-31 Rs5.68 Billion
≈ $61.44 Million
+21.16%
2009-03-31 Rs4.69 Billion
≈ $50.71 Million
+3.50%
2008-03-31 Rs4.53 Billion
≈ $48.99 Million
+8.26%
2007-03-31 Rs4.18 Billion
≈ $45.26 Million
+26.66%
2006-03-31 Rs3.30 Billion
≈ $35.73 Million
+16.26%
2005-03-31 Rs2.84 Billion
≈ $30.73 Million
--

Equity Component Analysis

This analysis shows how different components contribute to JB Chemicals & Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 3328626900000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2026)

Component Amount Percentage
Retained Earnings Rs33.29 Billion 80.03%
Common Stock Rs160.60 Million 0.39%
Other Components Rs8.15 Billion 19.58%
Total Equity Rs41.59 Billion 100.00%

JB Chemicals & Pharmaceuticals Limited Competitors by Market Cap

The table below lists competitors of JB Chemicals & Pharmaceuticals Limited ranked by their market capitalization.

Company Market Cap
Cleanaway Waste Management Ltd
AU:CWY
$3.82 Billion
Shanghai Phichem Material Co Ltd Class A
SHE:300398
$3.82 Billion
Changchun High & New Technology Industries Group Inc
SHE:000661
$3.83 Billion
Graham Holdings Co
NYSE:GHC
$3.83 Billion
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
$3.82 Billion
PT Alamtri Resources Indonesia Tbk
JK:ADRO
$3.81 Billion
ShenZhen Special Economic Zone Real Estate & Properties Group Co Ltd
SHE:000029
$3.81 Billion
Constellium SE
F:3OK
$3.81 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in JB Chemicals & Pharmaceuticals Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2025 to 2026, total equity changed from 34,333,200,000 to 41,592,200,000, a change of 7,259,000,000 (21.1%).
  • Net income of 7,094,700,000 contributed positively to equity growth.
  • Dividend payments of 3,132,900,000 reduced retained earnings.
  • New share issuances of 2,319,600,000 increased equity.
  • Other comprehensive income decreased equity by 3,226,496,000.
  • Other factors increased equity by 4,204,096,000.

Equity Change Factors (2025 to 2026)

Factor Impact Contribution
Net Income Rs7.09 Billion +17.06%
Dividends Paid Rs3.13 Billion -7.53%
Share Issuances Rs2.32 Billion +5.58%
Other Comprehensive Income Rs-3.23 Billion -7.76%
Other Changes Rs4.20 Billion +10.11%
Total Change Rs- 21.14%

Book Value vs Market Value Analysis

This analysis compares JB Chemicals & Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 8.44x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 62.32x to 8.44x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-03-31 Rs35.28 Rs2198.50 x
2006-03-31 Rs41.02 Rs2198.50 x
2007-03-31 Rs49.69 Rs2198.50 x
2008-03-31 Rs53.72 Rs2198.50 x
2009-03-31 Rs55.60 Rs2198.50 x
2010-03-31 Rs67.37 Rs2198.50 x
2011-03-31 Rs81.69 Rs2198.50 x
2012-03-31 Rs114.62 Rs2198.50 x
2013-03-31 Rs120.44 Rs2198.50 x
2014-03-31 Rs123.04 Rs2198.50 x
2015-03-31 Rs117.31 Rs2198.50 x
2016-03-31 Rs128.95 Rs2198.50 x
2017-03-31 Rs160.77 Rs2198.50 x
2018-03-31 Rs171.68 Rs2198.50 x
2019-03-31 Rs180.08 Rs2198.50 x
2020-03-31 Rs182.24 Rs2198.50 x
2021-03-31 Rs234.16 Rs2198.50 x
2022-03-31 Rs275.62 Rs2198.50 x
2023-03-31 Rs158.37 Rs2198.50 x
2024-03-31 Rs184.34 Rs2198.50 x
2025-03-31 Rs216.33 Rs2198.50 x
2026-03-31 Rs260.58 Rs2198.50 x

Capital Efficiency Dashboard

This dashboard shows how efficiently JB Chemicals & Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 17.06%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 17.10%
  • • Asset Turnover: 0.83x
  • • Equity Multiplier: 1.19x
  • Recent ROE (17.06%) is below the historical average (17.79%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 20.53% 16.26% 0.87x 1.45x Rs299.28 Million
2006 21.26% 15.08% 0.92x 1.53x Rs371.99 Million
2007 14.86% 11.83% 0.74x 1.70x Rs203.31 Million
2008 10.00% 8.06% 0.76x 1.64x Rs179.40K
2009 5.48% 3.59% 0.96x 1.59x Rs-211.79 Million
2010 20.90% 16.43% 0.86x 1.47x Rs619.41 Million
2011 20.15% 15.64% 0.89x 1.45x Rs701.69 Million
2012 69.89% 94.18% 0.60x 1.23x Rs5.81 Billion
2013 7.79% 10.12% 0.60x 1.27x Rs-225.83 Million
2014 5.90% 6.56% 0.69x 1.30x Rs-427.85 Million
2015 10.09% 9.59% 0.70x 1.49x Rs9.18 Million
2016 14.86% 13.93% 0.75x 1.42x Rs531.73 Million
2017 13.50% 14.06% 0.78x 1.23x Rs476.96 Million
2018 9.60% 10.01% 0.78x 1.22x Rs-58.15 Million
2019 13.07% 12.03% 0.90x 1.21x Rs454.54 Million
2020 18.95% 15.62% 0.96x 1.26x Rs1.28 Billion
2021 24.75% 22.19% 0.90x 1.24x Rs2.67 Billion
2022 18.06% 15.90% 0.93x 1.22x Rs1.72 Billion
2023 16.52% 13.15% 0.88x 1.43x Rs1.62 Billion
2024 18.90% 16.03% 0.86x 1.37x Rs2.60 Billion
2025 19.21% 17.08% 0.90x 1.24x Rs3.16 Billion
2026 17.06% 17.10% 0.83x 1.19x Rs2.94 Billion

Industry Comparison

This section compares JB Chemicals & Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $41,118,163,484
  • Average return on equity (ROE) among peers: 13.86%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Rs41.59 Billion 20.53% 0.19x $3.82 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) $366.97 Million 3.51% 2.41x $25.11 Million
Aarti Drugs Limited (AARTIDRUGS) $1.23 Billion 12.93% 2.27x $365.36 Million
Aarti Pharmalabs Limited (AARTIPHARM) $2.31 Million -8.08% 0.08x $645.54 Million
Abbott India Limited (ABBOTINDIA) $2.31 Billion 29.62% 0.43x $6.01 Billion
Ajanta Pharma Limited (AJANTPHARM) $32.64 Billion 21.83% 0.24x $4.15 Billion
Akums Drugs and Pharmaceutical (AKUMS) $7.23 Billion 13.11% 3.52x $996.26 Million
Alkem Laboratories Limited (ALKEM) $75.58 Billion 20.97% 0.52x $6.95 Billion
Amrutanjan Health Care Limited (AMRUTANJAN) $1.09 Billion 18.92% 0.29x $170.62 Million
Alembic Pharmaceuticals Limited (APLLTD) $22.20 Billion 18.58% 0.77x $1.59 Billion
Aurobindo Pharma Limited (AUROPHARMA) $268.52 Billion 7.18% 0.49x $8.98 Billion

About JB Chemicals & Pharmaceuticals Limited

NSE:JBCHEPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$3.82 Billion
Rs352.99 Billion INR
Market Cap Rank
#4310 Global
#185 in India
Share Price
Rs2198.50
Change (1 day)
+0.13%
52-Week Range
Rs1614.40 - Rs2257.70
All Time High
Rs2257.70
About

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dos… Read more